首页 > 市场调查报告书 > 製药

消化器

市场调查报告书

商品编码

1572509

非酒精性脂肪性肝炎治疗市场、机会、成长动力、产业趋势分析与预测，2024-2032

Non-alcoholic Steatohepatitis Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月21日 | 出版商:

Global Market Insights Inc. | 英文 159 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2023 年，全球非酒精性脂肪性肝炎(NASH) 治疗市场估值为55 亿美元，预计2024 年至2032 年复合年增长率为29.9%。这主要是由于肥胖和 2 型糖尿病发病率不断上升，并提高了人们对 NASH 作为关键健康问题的认识。

世界卫生组织 (WHO) 2022 年的报告指出，全球 43% 的成年人超重，其中 16% 属于肥胖。这些统计数据凸显了代谢疾病带来的全球健康挑战，包括 NASH 的风险增加。为此，从新药物疗法到强调体重管理的生活方式介入等创新治疗策略，加强了患者护理并推动了市场成长。

诊断技术的进步在推动市场方面发挥关键作用。增强的医疗技术和诊断方法使医疗保健专业人员能够更准确地检测和监测 NASH。这些方法的发展催生了侵入性较小但精确的诊断工具，这对于有效的疾病管理至关重要。美国肝病研究协会 (AASLD) 的报告指出，从 2010 年到 2020 年，非侵入性诊断工具的准确性提高了 40%。

整个非酒精性脂肪性肝炎治疗产业根据药物类型、给药途径、配销通路和地区进行划分。

维生素 E 和吡格列酮细分市场到 2023 年的市场份额将达到 17 亿美元。噻唑烷二酮类药物吡格列酮显示出良好的前景，特别是对于患有第 2 型糖尿病的 NASH 患者。维生素 E 的实惠性和安全性使其成为 NASH 患者的首选推荐，进一步推动市场成长。此外，吡格列酮能够提高 NASH 患者（尤其是糖尿病患者）的胰岛素敏感性并改善肝臟组织学，这凸显了其重要性。

到 2023 年，零售和专业药房领域的销售额将达到 27 亿美元。零售药局通常是患者的初步接触点，为疲劳等 NASH 症状提供非处方药和处方药解决方案。它们在确保可近性和可负担性方面的作用对于 NASH 等慢性病至关重要。专业药局专注于复杂药物，提供个人化服务，包括病患教育，这对于掌握 NASH 复杂的治疗方案至关重要。

北美 NASH 治疗市场预计将以 28.4% 的复合年增长率成长，到 2032 年将达到 232 亿美元。美国国家糖尿病、消化和肾臟疾病研究所 (NIDDK) 的数据显示，大约 24% 的美国成年人患有 NAFLD，其中 1.5% 至 6.5% 被诊断为 NASH。如果未经治疗，NASH 会带来严重的风险，包括肝硬化和肝癌。影响因素包括肥胖率上升、2 型糖尿病病例激增以及久坐的生活方式。市场的研发工作也显着增加，凸显了对有效治疗方法的追求。

产业生态系统分析
产业影响力
- 成长动力
  - 诊断技术的进步
  - NASH 盛行率增加
  - 提高对 NASH 的认识和诊断
- 产业陷阱与挑战
  - 治疗费用高
  - 副作用和安全问题
成长潜力分析
监管环境
管道分析
未来市场趋势
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司市占率分析
公司矩阵分析
主要市场参与者的竞争分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按药物类型，2021 - 2032

主要趋势
维生素E和吡格列酮
奥贝胆酸 (OCA)
索马鲁肽
塞隆塞提布
塞尼奇韦罗
其他药物类型

第 6 章：市场估计与预测：按管理途径，2021 年至 2032 年

主要趋势
口服
可注射

第 7 章：市场估计与预测：按配销通路，2021 - 2032 年

主要趋势
医院药房
零售和专业药局
其他分销管道

第 8 章：市场估计与预测：按地区，2021 - 2032

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 9 章：公司简介

AstraZeneca
Bristol-Myers Squibb Company
Conatus Pharmaceuticals
Galmed Pharmaceuticals
Genfit
Gilead Sciences, Inc.
Immuron Ltd
Intercept Pharmaceuticals, Inc.
Madrigal Pharmaceuticals
Novo Nordisk A/S
Takeda Pharmaceutical Company Limited
Zydus Cadila

简介目录

Product Code: 10894

The Global Non-alcoholic Steatohepatitis (NASH) Treatment Market was valued at USD 5.5 billion in 2023 and is projected to expand at a CAGR of 29.9% from 2024 to 2032. The market is driven by the rising prevalence of metabolic disorders, largely due to increasing obesity and type 2 diabetes rates, and heightened awareness of NASH as a critical health concern.

A 2022 report from the World Health Organization (WHO) noted that 43% of adults globally were overweight, with 16% classified as obese. These statistics highlight the global health challenge posed by metabolic diseases, including the heightened risk of developing NASH. In response, innovative treatment strategies, from new drug therapies to lifestyle interventions emphasizing weight management, bolster patient care and fuel market growth.

Advancements in diagnostic techniques play a pivotal role in propelling the market. Enhanced medical technologies and diagnostic methods empower healthcare professionals to detect and monitor NASH with greater accuracy. The evolution of these methods has birthed less invasive yet precise diagnostic tools, essential for effective disease management. A report from the American Association for the Study of Liver Diseases (AASLD) noted a 40% improvement in the accuracy of non-invasive diagnostic tools from 2010 to 2020.

The overall non-alcoholic steatohepatitis treatment industry is divided based on drug type, route of administration, distribution channel, and region.

The vitamin E and Pioglitazone segment commanded a market share of USD 1.7 billion in 2023. Vitamin E's antioxidant properties play a crucial role in treating NASH, helping to alleviate liver inflammation. Pioglitazone, from the thiazolidinedione class, shows promise, especially for NASH patients with type 2 diabetes. Its affordability and safety make vitamin E a go-to recommendation for NASH patients, further driving market growth. Additionally, pioglitazone's ability to boost insulin sensitivity and improve liver histology in NASH patients, especially diabetics, underscores its significance.

The retail and specialty pharmacies segment accounted for USD 2.7 billion in 2023. As NASH prevalence surges, driven by global obesity trends and metabolic syndrome incidences, the demand for effective therapies has skyrocketed. Retail pharmacies often serve as the initial touchpoint for patients, offering both over-the-counter and prescription solutions for NASH symptoms like fatigue. Their role in ensuring accessibility and affordability is vital for chronic conditions like NASH. Specialty pharmacies, focusing on complex medications, offer personalized services, including patient education, crucial for navigating NASH's intricate treatment regimens.

Projected to grow at a CAGR of 28.4%, North America NASH treatment market is set to reach USD 23.2 billion by 2032. The U.S. market expansion is closely tied to the rising NASH prevalence. Data from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) reveals that approximately 24% of U.S. adults have NAFLD, with 1.5% to 6.5% diagnosed with NASH. Untreated, NASH poses severe risks, including cirrhosis and liver cancer. Contributing factors include escalating obesity rates, a surge in type 2 diabetes cases, and increasingly sedentary lifestyles. The market also sees a notable uptick in research and development endeavors, underscoring the quest for effective treatments.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Advancements in diagnostic techniques
  - 3.2.1.2 Increasing prevalence of NASH
  - 3.2.1.3 Growing awareness and diagnosis of NASH
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost of treatment
  - 3.2.2.2 Side effects and safety concerns
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Future market trends
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Vitamin E and pioglitazone
5.3 Obeticholic acid (OCA)
5.4 Semaglutide
5.5 Selonsertib
5.6 Cenicriviroc
5.7 Other drug types

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Oral
6.3 Injectable

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospital pharmacies
7.3 Retail and specialty pharmacies
7.4 Other distribution channels

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa